Drug Discovery World
JULY 20, 2023
Compounds can be printed neat at 10mM in dimethyl sulfoxide (DMSO), and a unique data point is generated per target-ligand interaction. The technique is suited for targeting proteins and structured RNA, developing heterobifunctional degrader molecules (e.g., PROTAC), and training AI drug discovery models.
Drug Discovery World
OCTOBER 4, 2022
New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
FEBRUARY 22, 2024
With no in-house laboratory space, the company works closely with multiple international contract research organisations (CROs), including Axxam, which carry out all of the Libra R&D, from compound screening assays, to in vivo pharmacokinetic/pharmacodynamic and ADME work, as well as in vitro and in vivo pre-clinical safety assessments.
Drug Discovery World
JANUARY 23, 2023
But along with this massive disruption came an opportunity: to apply our platform to researching the SARS-CoV-2 virus. Our goal was to quickly identify existing therapeutics that could be repurposed for Covid-19 treatment by screening a library of approved and late-stage development drugs against a disease model in our platform.
Drug Discovery World
AUGUST 15, 2023
We suggest a new generation of screening assays, that better recapitulate the electrophysiology of the whole human heart, may allow better decisions across research and development. The models chosen can be surprisingly ‘under-evaluated’ given their powerful effect on the quality of research and development decisions.
Expert insights. Personalized for you.
40 
Let's personalize your content